Verrica Pharmaceuticals (VRCA) News Today $0.69 -0.01 (-1.31%) (As of 11:43 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Down 32.6% in NovemberDecember 15 at 2:54 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $9.60 Consensus PT from BrokeragesDecember 13, 2024 | americanbankingnews.comVerrica Pharmaceuticals Grants Stock Option to New COO David ZawitzDecember 12, 2024 | msn.comVerrica Pharmaceuticals Appoints New Chief Operating OfficerDecember 9, 2024 | tipranks.comVerrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 9, 2024 | globenewswire.comNew Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208December 7, 2024 | msn.comVerrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in JapanDecember 6, 2024 | globenewswire.comChester County firm expects to raise $42M after trimming staff and naming new CEONovember 23, 2024 | bizjournals.comVerrica Pharmaceuticals 44.96M share Spot Secondary priced at $0.89November 22, 2024 | markets.businessinsider.comVerrica Pharmaceuticals prices 44.96M shares at 89c in public offeringNovember 21, 2024 | markets.businessinsider.comVerrica Pharmaceuticals stock dips after pricing $42M securities offeringNovember 21, 2024 | msn.comVerrica Announces Pricing of $42.0 Million Public OfferingNovember 21, 2024 | globenewswire.comVerrica Pharmaceuticals announces common stock offering, no amount givenNovember 21, 2024 | markets.businessinsider.comVerrica Announces Proposed Public OfferingNovember 20, 2024 | globenewswire.comHold Rating on Verrica Pharmaceuticals Amidst Restructuring and Financial UncertaintyNovember 7, 2024 | markets.businessinsider.comRBC Capital Downgrades Verrica Pharmaceuticals (VRCA)November 7, 2024 | msn.comHC Wainwright Downgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to NeutralHC Wainwright lowered shares of Verrica Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comRBC downgrades Verrica Pharmaceuticals on ‘uncertain path’ forwardNovember 5, 2024 | markets.businessinsider.comVerrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results, Misses Estimates By $0.12 EPSVerrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) posted its earnings results on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of ($1.78) million for the quarter, compared to analysts' expectations of $7.53 million.November 5, 2024 | marketbeat.comVerrica Pharmaceuticals Undergoes Leadership and Financial RestructuringNovember 5, 2024 | markets.businessinsider.comVerrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Royal Bank of Canada to "Sector Perform"Royal Bank of Canada downgraded Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Tuesday.November 5, 2024 | marketbeat.comShares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational ChangesNovember 5, 2024 | marketwatch.comVerrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership TransitionNovember 5, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsOctober 30, 2024 | prnewswire.comShort Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Increases By 24.8%Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 4,530,000 shares, an increase of 24.8% from the September 30th total of 3,630,000 shares. Approximately 17.4% of the company's stock are sold short. Based on an average trading volume of 964,300 shares, the short-interest ratio is currently 4.7 days.October 28, 2024 | marketbeat.comVerrica to preset results on VP-315 at Fall Clinical Dermatology ConferenceOctober 25, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology ConferenceOctober 24, 2024 | globenewswire.comVerrica Pharmaceuticals price target lowered to $10 from $15 at TD CowenOctober 22, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from AnalystsVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been given an average rating of "Moderate Buy" by the five ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buyOctober 21, 2024 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD CowenTD Cowen cut their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday.October 21, 2024 | marketbeat.comVerrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...October 9, 2024 | finance.yahoo.comNeedham Downgrades Verrica Pharmaceuticals (VRCA)October 5, 2024 | msn.comVerrica Pharmaceuticals (NASDAQ:VRCA) Given New $11.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada reduced their target price on shares of Verrica Pharmaceuticals from $13.00 to $11.00 and set an "outperform" rating for the company in a report on Friday.October 4, 2024 | marketbeat.comVerrica Pharmaceuticals announces workforce reductionOctober 3, 2024 | uk.investing.comVerrica Pharmaceuticals to lay off about half of its staff in restructuringOctober 3, 2024 | bizjournals.comBrookline Capital Downgrades Verrica Pharmaceuticals (VRCA)October 3, 2024 | msn.comNeedham downgrades Verrica Pharmaceuticals (VRCA) to a HoldOctober 3, 2024 | markets.businessinsider.comVerrica downgraded to hold by Needham, cash position citedOctober 3, 2024 | msn.comVerrica Pharmaceuticals' (VRCA) "Hold" Rating Reiterated at Brookline Capital ManagementBrookline Capital Management reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday.October 2, 2024 | marketbeat.comVerrica Pharmaceuticals Announces Restructuring of Commercial OrganizationOctober 2, 2024 | globenewswire.comAttention Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): a Securities Fraud Class Action Has Survived a Motion to DismissSeptember 30, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy NowSeptember 29, 2024 | msn.comVERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCASeptember 27, 2024 | prnewswire.comNotice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): Grabar Law Office Investigates Claims on Your BehalfSeptember 26, 2024 | markets.businessinsider.comIs Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers?September 25, 2024 | finance.yahoo.com280,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Simplify Asset Management Inc.Simplify Asset Management Inc. purchased a new stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 280,000 shares of the company's stock, valuedSeptember 20, 2024 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Down 28.9% in AugustVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 2,980,000 shares, a decline of 28.9% from the August 15th total of 4,190,000 shares. Based on an average daily trading volume, of 651,900 shares, the short-interest ratio is presently 4.6 days. Approximately 11.5% of the company's shares are sold short.September 14, 2024 | marketbeat.comVerrica Pharmaceuticals CEO to Present at Global Investment ConferenceSeptember 6, 2024 | msn.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New YorkSeptember 4, 2024 | globenewswire.comWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?August 26, 2024 | finance.yahoo.com Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW VRCA Media Mentions By Week VRCA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRCA News Sentiment▼0.860.59▲Average Medical News Sentiment VRCA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRCA Articles This Week▼42▲VRCA Articles Average Week Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VXRT News CABA News IFRX News PLX News SAVA News APLT News ALGS News EDIT News IVA News ABOS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRCA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
